RU2016134406A - Композиции апилимода и способы их применения - Google Patents
Композиции апилимода и способы их применения Download PDFInfo
- Publication number
- RU2016134406A RU2016134406A RU2016134406A RU2016134406A RU2016134406A RU 2016134406 A RU2016134406 A RU 2016134406A RU 2016134406 A RU2016134406 A RU 2016134406A RU 2016134406 A RU2016134406 A RU 2016134406A RU 2016134406 A RU2016134406 A RU 2016134406A
- Authority
- RU
- Russia
- Prior art keywords
- apilimod
- composition
- additional active
- agents
- cell lymphoma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (23)
1. Способ лечения рака у пациента, нуждающегося в этом, включающий введение указанному пациенту терапевтически эффективного количества композиции апилимода, либо отдельно, либо в комбинации с одним или более дополнительных активных агентов.
2. Способ по п. 1, где композиция апилимода содержит свободное основание апилимода или димезилат апилимода.
3. Способ по п. 1 или 2, где композиция апилимода находится в пероральной лекарственной форме или лекарственной форме, подходящей для внутривенного введения.
4. Способ по любому из пп. 1-3, где злокачественное заболевание представляет собой лимфому, предпочтительно, В-клеточную лимфому, наиболее предпочтительно, неходжкинскую В-клеточную лимфому.
5. Способ по п. 4, где неходжкинская В-клеточная лимфома выбрана из диффузной крупноклеточной В-клеточной лимфомы (DLBCL), лимфомы Беркита, В-клеточной лимфомы средостения и лимфомы клеток мантии.
6. Способ по п. 4, где неходжкинская В-клеточная лимфома представляет собой DLBCL.
7. Способ по п. 6, где DLBCL представляет собой DLBCL-GCB.
8. Способ по любому из пп. 1-7, где способ включает введение апилимода в комбинации по меньшей мере с одним дополнительным активным агентом.
9. Способ по п. 8, где по меньшей мере один дополнительный активный агент представляет собой терапевтический агент или нетерапевтический агент, или их комбинации.
10. Способ по п. 8, где по меньшей мере один дополнительный активный агент вводят в одной лекарственной форме с композицией апилимода или в отдельных лекарственных формах с композицией апилимода.
11. Способ по п. 9 или 10, где по меньшей мере один дополнительный активный агент выбран из группы, состоящей из алкилирующего агента, интеркалирующего агента, агента, связывающего тубулин, кортикостероида и их комбинаций.
12. Способ по п. 9 или 10, где по меньшей мере один дополнительный активный агент представляет собой терапевтический агент, выбранный из группы, состоящей из ибрутиниба, ритуксимаба, доксорубицина, преднизолона, винкристина, велкада и эверолимуса, и их комбинаций.
13. Способ по п. 9 или 10, где по меньшей мере один дополнительный активный агент представляет собой терапевтический агент, выбранный из циклофосфамида, гидроксидаунорубицина (также называемого доксорубицином или Adriamycin™), винкристина (также называемого Oncovin™), преднизона, преднизолона и их комбинаций.
14. Способ по п. 9 или 10, где по меньшей мере один дополнительный активный агент представляет собой нетерапевтический агент, выбранный для облегчения одного или более побочных эффектов композиции апилимода.
15. Способ по п. 14, где нетерапевтический агент выбран из группы, состоящей из оданестрона, гранизетрона, долазетрона и палонозетрона.
16. Способ по п. 14, где нетерапевтический агент выбран из группы, состоящей из пиндолола и рисперидона.
17. Композиция апилимода для лечения рака у пациента, содержащая свободное основание апилимода или димезилат апилимода, в комбинации с одним или более из алкилирующих агентов, интеркалирующих агентов, агентов, связывающих тубулин и кортикостероидов.
18. Композиция по п. 17, где композиция содержит один или более агентов из ибрутиниба, ритуксимаба, доксорубицина, преднизолона, винкристина, велкада и эверолимуса.
19. Композиция по п. 18, где композиция содержит один или более агентов из преднизолона, велкада и эверолимуса.
20. Композиция по п. 18, где композиция содержит ибрутиниб.
21. Композиция по п. 18, где композиция содержит винкристин.
22. Композиция по любому из пп. 18-21, где композиция дополнительно содержит один или более агентов из оданестрона, гранизетрона, долазетрона, палонозетрона, пиндолола и рисперидона.
23. Способ по любому из пп. 1-16, или композиция по любому из пп. 17-22, где пациент страдает раком, который не поддается лечению или рецидивирует.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461931078P | 2014-01-24 | 2014-01-24 | |
US201461931075P | 2014-01-24 | 2014-01-24 | |
US61/931,075 | 2014-01-24 | ||
US61/931,078 | 2014-01-24 | ||
US201462077127P | 2014-11-07 | 2014-11-07 | |
US62/077,127 | 2014-11-07 | ||
PCT/US2015/012733 WO2015112888A1 (en) | 2014-01-24 | 2015-01-23 | Apilimod compositions and methods for using same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019107011A Division RU2019107011A (ru) | 2014-01-24 | 2015-01-23 | Композиции апилимода и способы их применения |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2016134406A true RU2016134406A (ru) | 2018-03-01 |
RU2016134406A3 RU2016134406A3 (ru) | 2018-09-20 |
Family
ID=53681989
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016134406A RU2016134406A (ru) | 2014-01-24 | 2015-01-23 | Композиции апилимода и способы их применения |
RU2019107011A RU2019107011A (ru) | 2014-01-24 | 2015-01-23 | Композиции апилимода и способы их применения |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019107011A RU2019107011A (ru) | 2014-01-24 | 2015-01-23 | Композиции апилимода и способы их применения |
Country Status (12)
Country | Link |
---|---|
US (3) | US10179135B2 (ru) |
EP (1) | EP3096757B1 (ru) |
JP (2) | JP6855243B2 (ru) |
KR (1) | KR102320190B1 (ru) |
CN (1) | CN106659716B (ru) |
AU (1) | AU2015209133B2 (ru) |
BR (1) | BR112016017112A2 (ru) |
CA (1) | CA2937655C (ru) |
IL (1) | IL246879B (ru) |
MX (1) | MX2016009590A (ru) |
RU (2) | RU2016134406A (ru) |
WO (1) | WO2015112888A1 (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2937655C (en) | 2014-01-24 | 2022-06-28 | Lam Therapeutics, Inc. | Apilimod compositions for cancer treatment |
JP6768682B2 (ja) * | 2014-11-07 | 2020-10-14 | エイアイ・セラピューティクス・インコーポレーテッド | メラノーマの処置に使用するためのアピリモド |
PT3215158T (pt) * | 2014-11-07 | 2019-08-23 | Ai Therapeutics Inc | Apilimod para utilização no tratamento de cancro renal |
WO2016118709A1 (en) * | 2015-01-23 | 2016-07-28 | Lam Therapeutics, Inc. | Anti-viral compositions containing pikfyve inhibitors and use thereof |
US20180078561A1 (en) * | 2015-03-31 | 2018-03-22 | Lam Therapeutics, Inc. | Active metabolites of apilimod and uses thereof |
TWI746449B (zh) * | 2015-07-20 | 2021-11-21 | 美商Ai治療公司 | 使用阿吡莫德治療癌症之方法 |
US20190015421A1 (en) * | 2016-01-21 | 2019-01-17 | Lam Therapeutics, Inc. | Biomarkers for Treating Cancer with Apilimod |
KR20180015441A (ko) | 2016-08-03 | 2018-02-13 | 엘지전자 주식회사 | 롤리 키보드 |
AU2017316475A1 (en) * | 2016-08-25 | 2019-03-07 | AI Therapeutics, Inc. | Compositions comprising PIKfyve inhibitors and methods related to inhibition of rank signaling |
CA3090807A1 (en) | 2018-02-21 | 2019-08-29 | AI Therapeutics, Inc. | Combination therapy with apilimod and glutamatergic agents |
CN108743947B (zh) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
CN110496128B (zh) * | 2019-09-23 | 2022-09-30 | 吉林大学 | 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用 |
JP2024521449A (ja) * | 2021-06-11 | 2024-05-31 | オルフアイ セラピューティクス インコーポレイテッド | 安定化されたアピリモドの組成物およびその使用方法 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
JP4071277B2 (ja) | 1993-11-12 | 2008-04-02 | ピーエイチアールアイ・プロパティーズ・インコーポレーテッド | 核酸検出用ハイブリダイゼーションプローブ、共通ステム、方法およびキット |
US6693097B2 (en) | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
ZA200606557B (en) | 2004-02-06 | 2008-02-27 | Elan Pharm Inc | Methods and compositions for treating tumors and metastatic disease |
US7745436B2 (en) | 2004-04-13 | 2010-06-29 | Synta Pharmaceuticals Corporation | Disalt inhibitors of IL-12 production |
CA2579096C (en) | 2004-09-08 | 2012-11-13 | Chelsea Therapeutics, Inc. | Quinazoline derivatives as metabolically inert antifolate compounds |
WO2006053112A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Process for preparing trisubstituted pyrimidine compounds |
TW200720256A (en) | 2005-05-13 | 2007-06-01 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
MY148491A (en) | 2005-11-17 | 2013-04-30 | Osi Pharm Inc | FUSED BICYCLIC mTOR INHIBITORS |
AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
EP1981890A2 (en) | 2006-01-25 | 2008-10-22 | OSI Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
PL2038252T3 (pl) | 2006-07-12 | 2017-03-31 | University Of Tennessee Research Foundation | Podstawione acyloanilidy i sposoby ich zastosowania |
AU2008213808B2 (en) | 2007-02-06 | 2011-11-10 | Novartis Ag | PI 3-kinase inhibitors and methods of their use |
RU2438664C2 (ru) | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
JP5258331B2 (ja) * | 2008-03-03 | 2013-08-07 | ロート製薬株式会社 | 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物 |
US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
WO2010006438A1 (en) | 2008-07-17 | 2010-01-21 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
EP4201402A1 (en) | 2010-03-08 | 2023-06-28 | Sloan-Kettering Institute For Cancer Research | Cdc7 kinase inhibitors and uses thereof |
JP5783499B2 (ja) | 2010-03-29 | 2015-09-24 | 味の素株式会社 | フェニルアラニン誘導体を含有する医薬製剤 |
US8402515B2 (en) | 2010-05-06 | 2013-03-19 | Jonathan Weizman | Apparatus and method for establishing a peer-to-peer communication session with a client device |
WO2011146727A1 (en) * | 2010-05-19 | 2011-11-24 | Philip Bosch | Methods of treating interstitial cystitis |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
GEP201606545B (en) * | 2010-11-19 | 2016-09-26 | Ecole Polytech | 2-piperazin-1-yl-4h-1,3-benzo-thiazin-4-one derivatives and their use for treatment of mammalian infections |
WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
SG11201407190TA (en) | 2012-05-15 | 2014-12-30 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
EP2903644A4 (en) | 2012-10-05 | 2016-03-09 | Cerulean Pharma Inc | TREATMENT OF CANCER |
US9295731B2 (en) | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
CA2937655C (en) | 2014-01-24 | 2022-06-28 | Lam Therapeutics, Inc. | Apilimod compositions for cancer treatment |
JP6768682B2 (ja) | 2014-11-07 | 2020-10-14 | エイアイ・セラピューティクス・インコーポレーテッド | メラノーマの処置に使用するためのアピリモド |
PT3215158T (pt) | 2014-11-07 | 2019-08-23 | Ai Therapeutics Inc | Apilimod para utilização no tratamento de cancro renal |
US20180015098A1 (en) | 2015-02-03 | 2018-01-18 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
US20180078561A1 (en) | 2015-03-31 | 2018-03-22 | Lam Therapeutics, Inc. | Active metabolites of apilimod and uses thereof |
TWI746449B (zh) | 2015-07-20 | 2021-11-21 | 美商Ai治療公司 | 使用阿吡莫德治療癌症之方法 |
AU2019299234A1 (en) | 2018-07-05 | 2021-01-14 | Mayo Foundation For Medical Education And Research | PIKfyve inhibitors |
US20210077500A1 (en) | 2019-09-12 | 2021-03-18 | Al Therapeutics, Inc. | Pikfyve inhibitors for cancer therapy |
-
2015
- 2015-01-23 CA CA2937655A patent/CA2937655C/en active Active
- 2015-01-23 EP EP15740043.3A patent/EP3096757B1/en active Active
- 2015-01-23 US US15/113,154 patent/US10179135B2/en active Active
- 2015-01-23 AU AU2015209133A patent/AU2015209133B2/en active Active
- 2015-01-23 MX MX2016009590A patent/MX2016009590A/es active IP Right Grant
- 2015-01-23 BR BR112016017112A patent/BR112016017112A2/pt not_active Application Discontinuation
- 2015-01-23 RU RU2016134406A patent/RU2016134406A/ru not_active Application Discontinuation
- 2015-01-23 JP JP2016548172A patent/JP6855243B2/ja active Active
- 2015-01-23 RU RU2019107011A patent/RU2019107011A/ru unknown
- 2015-01-23 KR KR1020167022474A patent/KR102320190B1/ko active IP Right Grant
- 2015-01-23 WO PCT/US2015/012733 patent/WO2015112888A1/en active Application Filing
- 2015-01-23 CN CN201580016018.3A patent/CN106659716B/zh active Active
-
2016
- 2016-07-21 IL IL246879A patent/IL246879B/en active IP Right Grant
-
2018
- 2018-11-16 US US16/193,045 patent/US20190183902A1/en not_active Abandoned
-
2019
- 2019-12-27 US US16/728,566 patent/US11266654B2/en active Active
-
2020
- 2020-12-04 JP JP2020201440A patent/JP2021046430A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2016134406A3 (ru) | 2018-09-20 |
EP3096757A4 (en) | 2017-10-04 |
JP2017503842A (ja) | 2017-02-02 |
NZ722491A (en) | 2021-01-29 |
US20190183902A1 (en) | 2019-06-20 |
IL246879A0 (en) | 2016-08-31 |
RU2019107011A (ru) | 2019-04-08 |
JP2021046430A (ja) | 2021-03-25 |
CA2937655C (en) | 2022-06-28 |
JP6855243B2 (ja) | 2021-04-07 |
US10179135B2 (en) | 2019-01-15 |
KR102320190B1 (ko) | 2021-11-03 |
MX2016009590A (es) | 2017-05-09 |
BR112016017112A2 (pt) | 2017-08-08 |
US20200268764A1 (en) | 2020-08-27 |
IL246879B (en) | 2020-05-31 |
EP3096757B1 (en) | 2020-10-21 |
WO2015112888A1 (en) | 2015-07-30 |
CN106659716B (zh) | 2021-03-12 |
US11266654B2 (en) | 2022-03-08 |
US20170007613A1 (en) | 2017-01-12 |
AU2015209133A1 (en) | 2016-08-11 |
EP3096757A1 (en) | 2016-11-30 |
CN106659716A8 (zh) | 2017-06-30 |
KR20160126984A (ko) | 2016-11-02 |
CN106659716A (zh) | 2017-05-10 |
AU2015209133B2 (en) | 2019-10-03 |
CA2937655A1 (en) | 2015-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016134406A (ru) | Композиции апилимода и способы их применения | |
JP2017503842A5 (ru) | ||
JP2020505433A5 (ru) | ||
RU2007130991A (ru) | Составы, обладающие антиканцерогенными свойствами | |
RU2010118448A (ru) | Комбинированная терапия антителами анти-cd20 типа ii в сочетании с активным агентом анти-bcl-2 | |
NZ723271A (en) | Fused imidazole derivatives useful as ido inhibitors | |
WO2007084670A3 (en) | Specific therapy using integrin ligands for treating cancer | |
HRP20220718T1 (hr) | Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka | |
WO2021050953A8 (en) | Compositions and methods for the delivery of therapeutic biologics for treatment of disease | |
RU2015118135A (ru) | Содержащие заместители бензольные соединения | |
WO2004096224A3 (en) | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | |
RU2008138560A (ru) | Улучшенные способы лечения опухолей | |
WO2020102804A3 (en) | Pharmaceutical combination for treatment of cancer | |
MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
WO2005081742A3 (en) | Testosterone oral dosage formulations and associated methods | |
MY168791A (en) | Carbamate compounds and of making and using same | |
BR112015009559A2 (pt) | uso de composto antissenso na preparação de medicamento para tratamento de cãncer, composto antissenso e composição farmacêutica | |
WO2009010287A3 (en) | Specific therapy and medicament using integrin ligands for treating cancer | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
RU2012147340A (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR | |
RU2018105923A (ru) | Способы лечения рака с использованием апилимода | |
BR0206046A (pt) | Usos de uma combinação e de sapogenina protopanaxadiol ou sapogenina protopanaxatriol, e, composição farmacêutica | |
RU2017119065A (ru) | Апилимод для применения в лечении рака почек | |
RU2012109451A (ru) | Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном | |
JP2018503610A5 (ru) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20200316 |